Clinical trials: Relapsed and/or Refractory Multiple Myeloma, open to volunteers
B Cell Lymphoma, Multiple Mieloma
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints.
- Trial name
- CARBIOM (NCT07852377)
- Testing
- Biological sample collection and immunomonitoring
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
Multiple Myeloma, Carfilzomib
The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients
This study is a prospective, single center, single arm phase II clinical trial. The study population consists of patients who have received treatment with VRd or VRd lite regimens for 2-8 courses in the past and have achieved…
- Conditions
- Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
- Trial name
- DKPD (NCT07015021)
- Testing
- Daratumumab, Cafizomide, Pomalidomide
- Volunteers
- 72 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, first in human, study to evaluate the safety and the effects of in vivo BCMA-CAR T cell therapy (VV169) in patients with Multiple Myeloma that has been previously treated and has come back, or does not respond to…
- Trial name
- NCT07802717
- Testing
- VV169
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vyriad, Inc.
Relapsed or Refractory Multiple Myeloma (RRMM)
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - CD19 CAR-T cell therapy.
- Trial name
- NCT07003555
- Testing
- Dual-targeting BCMA-CD19 CAR-T cell infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Relapsed or Refractory Multiple Myeloma (RRMM)
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT07715630
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed or Refractory Multiple Myeloma
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT07116616
- Testing
- mRNA-2808
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ModernaTX, Inc.
Multiple Myeloma
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) / interleukin-15 (IL-15) manufactured CAR T cells in adult patients with…
- Trial name
- NCT05976555
- Testing
- BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg), BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
This is a multicenter, open-label study to evaluate the safety and efficacy of C-CAR088 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05521802
- Testing
- B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Shanghai AbelZeta Ltd.
Multiple Myeloma (MM)
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT07910903
- Testing
- CM336, CM313, Daratumumab
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Keymed Biosciences Co.Ltd
Multiple Myeloma
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT07105059
- Testing
- Teclistamab, Mezigdomide
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and…
- Trial name
- DOMMINO-1 (NCT07096778)
- Testing
- Inobrodib, Pomalidomide, Dexamethasone
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- CellCentric Ltd.
Relapsed/Refractory Systemic Light Chain Amyloidosis
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again.
- Trial name
- LINKER-AL2 (NCT06292780)
- Testing
- Linvoseltamab
- Where
- 21 sites in United States, Greece and 4 more
- Volunteers
- 220 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Multiple Myeloma
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
- Trial name
- NCT06988488
- Testing
- Elranatamab, Mezigdomide, Dexamethasone
- Where
- 22 sites in United States, Canada and 6 more
- Volunteers
- 62 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
This clinical trial aims to characterize the safety of OL-101 and establish the recommended dose for future research and to evaluate the efficacy of OL-101 (Dose expansion).
- Trial name
- NCT06644118
- Testing
- OL-101 infusion
- Where
- 3 sites in China
- Volunteers
- 58 people
- Sponsor
- Zhejiang University
Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Despite advances in multiple myeloma (MM) therapy, patients continue to suffer from frequent relapses and treatment-resistant disease.
- Trial name
- Mezi-KD (NCT07348393)
- Testing
- Administration of a combination of treatments
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsed or Refractory Multiple Myeloma
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and…
- Trial name
- NCT07018050
- Testing
- QLS32015, Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
- Conditions
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma
- Trial name
- NCT04162353
- Testing
- BCMA-CD19 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- iCell Gene Therapeutics
AML, Multiple Myeloma
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
To assess safety and tolerability at increasing dose levels of 6MW5311 in successive cohorts of participants with MM, AML and CMML in order to estimate the maximum tolerated dose (MTD) and select the recommended Phase 2 dose…
- Conditions
- AML, Multiple Myeloma, CMML
- Trial name
- NCT07914556
- Testing
- 6MW5311
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.